Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report) and ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical and Nevro Preliminary Full-Year 2024 Revenue Outlook: On January 8, 2025, Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year ...

Globus Medical said the purchase would increase its portfolio of musculoskeletal technologies, therefore enhancing its position in neuromodulation and chronic pain management. Nevro, with its ...

Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's ...

Brave is the woman in a transparent heel bearing the human foot in all its anatomical nakedness. These are difficult shoes to make work (a sort of non-item anchoring an outfit to nothing), which ...

Globus Medical has a 12 month low of $49.33 and a 12 month high of $94.93. Globus Medical ( NYSE:GMED – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 5th.

Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an all-cash ...

The CEO of Globus Medical said the deal will enable the Audubon company to expand into new markets for future growth. Montgomery County's Globus Medical has agreed to acquire a California life ...

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Globus Medical (NYSE:GMED) in the last three months. In the table below, you'll find a ...